Neuromodulation Device Articles & Analysis
29 news found
BlueWind Medical, Ltd., developer of the innovative RENOVA™ iStim implantable neuromodulation device for treatment of Overactive Bladder, today announced additions to its leadership team in preparation for commercialization of the RENOVA product line. ...
(NASDAQ: CVRX) ("CVRx"), developer of the world's first FDA-approved neuromodulation device to treat the symptoms of heart failure, has launched its new Barostim Programmer, which was approved by the U.S. ...
ByCVRx
The Relivion DP is the first non-invasive, multi-channel brain neuromodulation system for at home treatment of neurological and neuropsychiatric disorders. ...
Neurolief, an Israel-based company pioneering neuromodulation for the treatment of chronic neurological and neuropsychiatric disorders, and NeuroFront, a clinical stage biotech company focusing on innovative neuroscience therapies, jointly announced an exclusive licensing agreement for NeuroFront to develop and commercialize Relivion, non-invasive medical devices ...
About Neurolief Dedicated to bringing relief to patients suffering from chronic neurological and neuropsychiatric disorders, Neurolief is creating a digital therapeutics platform of wearable clinically proven neuromodulation solutions. This technology, which is made to be worn like a headset, is intended to offer highly effective, safe treatment options that work either as an ...
Neuspera Medical, a medical device company developing implantable devices for patients battling chronic illnesses, today announced it will begin enrollment in its pivotal clinical trial (SANS-UUI), a single-arm study that will enroll 145 patients at 25 sites globally. ...
MINNEAPOLIS, June 10, 2021 - CVRx©. developer of the world's first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF). announced the completion of the first clinical procedure with the company's new lead implantation approach. ...
ByCVRx
Neurolief, a neurotechnology innovator, today announces the publication of the SP301 study in the Pain and Therapy Journal that demonstrates the safety and efficacy of Relivion MG, Neurolief’s CE-marked and FDA cleared wearable neuromodulation system for at-home treatment of migraine with remote physician monitoring. ...
(NASDAQ: CVRX) ("CVRx"), developer of the world's first FDA-approved neuromodulation device to treat the symptoms of heart failure, has received U.S. ...
ByCVRx
Bluewind Medical, Ltd., developer of the innovative RENOVA iStim implantable neuromodulation device for treatment of urinary urgency incontinence, today announced it will be participating in the 33rd Annual Virtual Healthcare Conference organized by Piper Sandler on Nov 29th – Dec 2nd, 2021. ...
Bluewind Medical, Ltd., developer of the innovative RENOVA™ iStim implantable neuromodulation device for treatment of urinary urgency incontinence, today announced it will be participating in the 33rd Annual Virtual Healthcare Conference organized by Piper Sandler on Nov 29th – Dec 2nd, 2021. ...
Bluewind Medical, Ltd., developer of the innovative RENOVA iStim implantable neuromodulation device for treatment of urinary urgency incontinence, today announced the successful completion of patient enrollment in the OASIS pivotal clinical study that will be the basis by which the company will seek US-FDA (Food & Drug Administration) marketing clearance in ...
Dr Steinhaus has extensive clinical and business experience in cardiac rhythm management, including performing numerous clinical studies in implantable cardiac devices and leads. He is currently the Executive Chairman of the board at Enopace Biomedical Ltd., a company which produces therapeutic neuromodulation devices for the treatment of heart ...
Nerivio, a drug-free remote electrical neuromodulation (REN) device for the acute treatment of migraine in patients 12 years and older, delivers electrical waveform to nerve fibers at the upper arm, to trigger the conditioned pain modulation in the central nervous system, activating the body's endogenous analgesic mechanism. ...
Neuspera Medical Inc. is a medical device company that leverages both exclusively licensed and proprietary power transfer techniques to engineer miniaturized neuromodulation technologies – sometimes referred to as bioelectronic medicines. Neuspera’s hermetically sealed implantable modules are more than 100 times smaller than ...
Image courtesy of Bigfoot Biomedical private medtech companies to watch – Bigfoot Biomedical Cala Health Cala Health is a Burlingame, CA-based company developing the FDA-cleared Cala Trio, a wearable neuromodulation device designed to look like a watch, with the “watch face” being the stimulator and the band housing electrodes that target the ...
“The FDA clearance of the Relivion® non-invasive device is an important event for those suffering from migraines, as it is the only neuromodulation technology thus far that has demonstrated statistically significant efficacy in providing complete freedom of migraine symptoms within 2 hours after treatment, in a sham-controlled clinical trial,” ...
"Over the last couple of years our toolbox for treating migraine has been enriched with several new types of FDA-authorized therapies, including a few drug-free neuromodulation devices," said Christopher Gottschalk, MD, a Yale Medicine neurologist and director of Yale Medicine's Headache and Facial Pain Center, who also serves as the president of the Alliance for ...
If Relivion® is approved by the agency, it will be the only brain neuromodulation device available for treatment at home in Japan. *In Europe, Neurolief obtained the CE Mark certification as a treatment device for migraine and is in preparation for the market launch. ...
Tepper. The Relivion® enables neuromodulation of brain networks associated with control of pain and other migraine related symptoms. ...